Company Overview and News


Add BMYMP
to your dashboard

Headline News

Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement

18h seekingalpha
Today we will discuss an article on Conatus Pharmaceuticals (CNAT) by Stephen Ayers, titled, “Conatus: Likely To Dash Ahead Of NASH Data.” (163-0)

How Did Bristol-Myers Squibb Perform in 3Q17?

2017-11-29 marketrealist
In 3Q17, Bristol-Myers Squibb (BMY) reported revenues of $5.3 billion, a ~7% increase on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis. Bristol-Myers Squibb reported revenues of $14.2 billion in the first nine months of 2017 compared to $12.9 billion in the corresponding period of 2016. (72-0)

Bristol-Myers Squibb (BMY) Presents at 2017 Evercore ISI Biopharma Catalyst/Deep Dive Conference (Transcript)

2017-11-29 seekingalpha
Okay. Great. Well, thank you all for joining us. Pleasure to have Fouad from Bristol-Myers' Head of Oncology Development join us. Fouad, thank you for joining us. Thank you, John for being here. I also said John should be here, but John like to keep it low-key right now, but we'll keep coming back to you. (75-0)

Biotech Investment and Deal-making are Front and Center at #BIOCEO18

2017-11-29 biotech-now.org
The business of making life-saving treatments is fraught with setbacks, challenges and failures. Along the way, new discoveries may pivot searches in new directions. Failures are not necessarily the end of the journey, and with each setback, new data is added to future research. Consider the recent CAR-T cell immunotherapy approvals by the FDA, ushering in a new era of exciting new medicines. These therapies have been in development for a least two decades requiring sustained infusions of cash and a solid commitment to bring concept to reality. (337-0)

Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

2017-11-29 zacks
It was a relatively slow week given the Thanksgiving break. Key developments this week include Biogen’s (BIIB - Free Report) deal with Alkermes (ALKS - Free Report) and Regeneron’s (REGN - Free Report) disappointing data on Eylea. Recap of the Week’s Most Important Stories Biogen Inks Deal with Alkermes for MS Drug: Biogen, a key player in the multiple sclerosis (“MS”) market, has signed up with Alkermes for the worldwide development and commercialization of ALKS 8700. (302-0)

Hold On To Nektar Therapeutics: There Is Much More Ammunition Left In Its Partnered Research Programs

2017-11-29 seekingalpha
Nektar Therapeutics is a biopharmaceutical company which depends heavily on payments received from partners. The company has either collaborated with pharmaceutical players for developing novel drugs targeting multiple therapeutic areas or has out licensed its PEGylated polymer conjugation technology. The limited amount of direct product sales coupled with concoction of upfront payments, milestone payments, royalties, and licensing fees from leading companies such as Shire (SHPG), AstraZeneca (AZN), Bayer, Amgen (AMGN) and others makes it pretty difficult to predict revenue growth for the company on quarterly basis. (233-0)

Gilead Sciences: Are You Willing To Wait 3 Years?

2017-11-27 seekingalpha
While this move into immunotherapy for oncology is a great play, it won't show results to earnings for three years. (92-0)

How Soros And Buffett Inform An Updated View Of Trading Apple

2017-11-26 seekingalpha
As some smaller techs melt up, such as NVDA and ADBE, AAPL remains at a below-market P/E. (358-1)

ESMO: Clovis CEO deems new Rubraca data 'better' than its PARP rivals. Is it enough? | FiercePharma

2017-11-25 fiercepharma
MADRID, Spain—Clovis Oncology may be the middle child in the new wave of ovarian cancer treatments, but it’s hoping some new data will take it to the head of the PARP class. (104-2)

How Johnson & Johnson’s Revenues Trended in 3Q17

2017-11-24 marketrealist
Johnson & Johnson (JNJ) reported revenue growth of 10.3% to $19.7 billion during 3Q17 as compared to $17.8 billion during 3Q16, which includes operational growth of 9.5% and a 0.8% positive impact of foreign exchange during 3Q17. (72-0)

Johnson & Johnson Reports Revenue Growth in 3Q17

2017-11-24 marketrealist
Johnson & Johnson (JNJ) reported 10.3% growth in its revenues to $19.7 billion during 3Q17, as compared to revenues of $17.8 billion in 3Q16. The company surpassed Wall Street analysts’ estimates for the EPS (or earnings per share) and reported EPS of $1.91 for 3Q17 as compared to the estimates of $1.80. (77-0)

Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

2017-11-24 zacks
Shares of Nektar Therapeutics (NKTR - Free Report) have been up almost 306% this year so far, substantially outperforming the industry’s increase of 3.9% during the period. Let’s analyze the factors that led to this massive rally. (184-2)

Anemic Quant Score Restrict Bristol-Myers Squibb Co (BMY) Rating

2017-11-24 investorplace
Bristol-Myers Squibb Co (NYSE:BMY) is ranked as a Hold using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BMY has had from Portfolio Grader for 2 months. (72-0)

Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?

2017-11-23 seekingalpha
Shares have risen by 75% since bringing this stock to the attention of readers three weeks ago. (388-4)

Bayer pharmaceuticals head says there's no pipeline problem - Channel NewsAsia

2017-11-23 channelnewsasia
LEVERKUSEN, Germany: Bayer is seeking to defend its pharmaceuticals business that will be diluted in importance by the takeover of Monsanto and faces a threat to revenues in 2024 when the blockbuster heart drug Xarelto loses its patent. (85-0)

CUSIP: 110122908